Targeted delivery of deoxycytidine kinase to Her2-positive cells enhances the efficacy of the nucleoside analog fludarabine

PLoS ONE

Volumn 11, Issue 6, 2016, Pages

  Koduvayur, Sujatha P ^a,c   Su, Ying ^a   Kay, Brian K ^a   Lavie, Arnon ^a,b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b JESSE BROWN VA MEDICAL CENTER   (United States)

^c Stevens Institute of Technology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANKYRIN; ANTIBODY; DEOXYCYTIDINE KINASE; DESIGNED ANKYRIN REPEAT PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUDARABINE; HER2 ANTIBODY; UNCLASSIFIED DRUG; ERBB2 PROTEIN, HUMAN; VIDARABINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BT 474 JB CELL LINE; CANCER CELL LINE; CELL PROLIFERATION ASSAY; DRUG ACTIVATION; DRUG BINDING; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG TARGETING; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; INTERNALIZATION; JIMT 1 CELL LINE; MCF 7 CELL LINE; SK OV 3 CELL LINE; ANALOGS AND DERIVATIVES; APOPTOSIS; BREAST NEOPLASMS; CELL PROLIFERATION; FEMALE; GENETICS; METABOLISM; MULTIMODALITY CANCER THERAPY; OVARIAN NEOPLASMS; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL CULTURE;

APOPTOSIS; BREAST NEOPLASMS; CELL PROLIFERATION; COMBINED MODALITY THERAPY; DEOXYCYTIDINE KINASE; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; OVARIAN NEOPLASMS; PHOSPHORYLATION; RECEPTOR, ERBB-2; TUMOR CELLS, CULTURED; VIDARABINE;

EID: 84975461212     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0157114     Document Type: Article

References (42)

1. Jordheim LP, Durantel D, Zoulim F, Dumontet C. Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. Nat Rev Drug Discov. 2013; 12:447-64. doi: 10.1038/nrd4010 PMID: 23722347
2. Galmarini CM, Mackey JR, Dumontet C. Nucleoside analogues and nucleobases in cancer treatment. Lancet Oncol. 2002; 3:415-24. PMID: 12142171
3. Strebhardt K, Ullrich A. Paul Ehrlich's magic bullet concept: 100 years of progress. Nat Rev Cancer. 2008; 8:473-80. doi: 10.1038/nrc2394 PMID: 18469827
4. Leal M, Sapra P, Hurvitz SA, Senter P, Wahl A, Schutten M, et al. Antibody-drug conjugates: an emerging modality for the treatment of cancer. Ann N Y Acad Sci. 2014; 1321:41-54. doi: 10.1111/nyas.12499 PMID: 25123209
5. Lambert JM. Drug-conjugated antibodies for the treatment of cancer. Br J Clin Pharmacol. 2013; 76:248-62. doi: 10.1111/bcp.12044 PMID: 23173552
6. Burris HA. Developments in the use of antibody-drug conjugates. Am Soc Clin Oncol Educ Book. 2013.
7. Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJ. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov. 2010; 9:325-38. doi: 10.1038/nrd3003 PMID: 20305665
8. Lambert JM. Drug-conjugated monoclonal antibodies for the treatment of cancer. Curr Opin Pharmacol. 2005; 5:543-9. PMID: 16087399
9. Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004; 93:2645-68. PMID: 15389672
10. Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res. 2001; 7:1490-6. PMID: 11410481
11. McDonagh CF, Turcott E, Westendorf L, Webster JB, Alley SC, Kim K, et al. Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment. Protein Eng Des Sel. 2006; 19:299-307. PMID: 16644914
12. Chari RV. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res. 2008; 41:98-107. PMID: 17705444
13. Singh Y, Palombo M, Sinko PJ. Recent trends in targeted anticancer prodrug and conjugate design. Curr Med Chem. 2008; 15:1802-26. PMID: 18691040
14. Koshkaryev A, Sawant R, Deshpande M, Torchilin V. Immunoconjugates and long circulating systems: origins, current state of the art and future directions. Adv Drug Deliv Rev. 2013; 65:24-35. doi: 10.1016/j.addr.2012.08.009 PMID: 22964425
15. Alley SC, Benjamin DR, Jeffrey SC, Okeley NM, Meyer DL, Sanderson RJ, et al. Contribution of linker stability to the activities of anticancer immunoconjugates. Bioconjug Chem. 2008; 19:759-65. doi: 10.1021/bc7004329 PMID: 18314937
16. Firer MA, Gellerman G. Targeted drug delivery for cancer therapy: the other side of antibodies. J Hematol Oncol. 2012; 5:70. doi: 10.1186/1756-8722-5-70 PMID: 23140144
17. Yu D, Hung MC. Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene. 2000; 19:6115-21. PMID: 11156524
18. Tamaskovic R, Simon M, Stefan N, Schwill M, Pluckthun A. Designed ankyrin repeat proteins (DAR-Pins) from research to therapy. Methods Enzymol. 2012; 503:101-34. doi: 10.1016/B978-0-12-396962-0.00005-7 PMID: 22230567
19. Lofblom J, Feldwisch J, Tolmachev V, Carlsson J, Stahl S, Frejd FY. Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett. 2010; 584:2670-80. doi: 10.1016/j.febslet.2010.04.014 PMID: 20388508
20. Sabini E, Ort S, Monnerjahn C, Konrad M, Lavie A. Structure of human dCK suggests strategies to improve anticancer and antiviral therapy. Nat Struct Biol. 2003; 10:513-9. PMID: 12808445
21. Zahnd C, Amstutz P, Pluckthun A. Ribosome display: selecting and evolving proteins in vitro that specifically bind to a target. Nat Methods. 2007; 4:269-79. PMID: 17327848
22. Friedman M, Nordberg E, Hoiden-Guthenberg I, Brismar H, Adams GP, Nilsson FY, et al. Phage display selection of Affibody molecules with specific binding to the extracellular domain of the epidermal growth factor receptor. Protein Eng Des Sel. 2007; 20:189-99. PMID: 17452435
23. Vlashi E, Sturgis JE, Thomas M, Low PS. Real time, noninvasive imaging and quantitation of the accumulation of ligand-targeted drugs into receptor-expressing solid tumors. Mol Pharm. 2009; 6:1868-75. doi: 10.1021/mp900158d PMID: 19754150
24. Steiner M, Neri D. Antibody-radionuclide conjugates for cancer therapy: historical considerations and new trends. Clin Cancer Res. 2011; 17:6406-16. doi: 10.1158/1078-0432.CCR-11-0483 PMID: 22003068
25. Ricci F, Tedeschi A, Morra E, Montillo M. Fludarabine in the treatment of chronic lymphocytic leukemia: a review. Ther Clin Risk Manag. 2009; 5:187-207. PMID: 19436622
26. Barrueco JR, Jacobsen DM, Chang CH, Brockman RW, Sirotnak FM. Proposed mechanism of therapeutic selectivity for 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia based upon lower capacities for transport and phosphorylation in proliferative intestinal epithelium compared to tumor cells. Cancer Res. 1987; 47:700-6. PMID: 3802076
27. Ross SR, McTavish D, Faulds D. Fludarabine. A review of its pharmacological properties and therapeutic potential in malignancy. Drugs. 1993; 45:737-59. PMID: 7686467
28. Plunkett W, Gandhi V, Huang P, Robertson LE, Yang LY, Gregoire V, et al. Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies. Semin Oncol. 1993; 20:2-12.
29. Avramis VI, Plunkett W. Metabolism and therapeutic efficacy of 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia P388. Cancer Res. 1982; 42:2587-91. PMID: 7083151
30. Zahnd C, Wyler E, Schwenk JM, Steiner D, Lawrence MC, McKern NM, et al. A designed ankyrin repeat protein evolved to picomolar affinity to Her2. J Mol Biol. 2007; 369:1015-28. PMID: 17466328
31. Campbell DO, Yaghoubi S.S., Su Y., Lee J.T., Auerbach M.S., Herschman H., Satyamurthy N., Czernin J., Lavie A., and Radu C.G. Structure-guided Engineering of Human Thymidine Kinase 2 as a Positron Emission Tomography Reporter Gene for Enhanced Phosphorylation of Non-natural Thymidine Analog Reporter Probe. Journal of Biological Chemistry. 2012; 287:446-54. doi: 10.1074/jbc.M111.314666 PMID: 22074768
32. Koduvayur SP, Gussin HA, Parthasarathy R, Hao Z, Kay BK, Pepperberg DR. Generation of recombinant antibodies to rat GABAA receptor subunits by affinity selection on synthetic peptides. PLoS One. 2014; 9:e87964. doi: 10.1371/journal.pone.0087964 PMID: 24586298
33. Orlova A, Magnusson M, Eriksson TL, Nilsson M, Larsson B, Hoiden-Guthenberg I, et al. Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res. 2006; 66:4339-48. PMID: 16618759
34. Choo H-S, Mason K., Ramyar K.X., Stanley A.M., Gabelli S.B., Denney D.W. Jr., and, Leahy D.J. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature. 2003; 421:756-60. PMID: 12610629
35. Fogh J, Fogh JM, Orfeo T. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J Natl Cancer Inst. 1977; 59:221-6. PMID: 327080
36. Lasfargues EY, Coutinho WG, Redfield ES. Isolation of two human tumor epithelial cell lines from solid breast carcinomas. J Natl Cancer Inst. 1978; 61:967-78. PMID: 212572
37. Soule HD, Vazguez J, Long A, Albert S, Brennan M. A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst. 1973; 51:1409-16. PMID: 4357757
38. Hudis CA. Trastuzumab - mechanism of action and use in clinical practice. N Engl J Med. 2007; 357:39-51. PMID: 17611206
39. Canonici A, Gijsen M, Mullooly M, Bennett R, Bouguern N, Pedersen K, et al. Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer. Oncotarget. 2013; 4:1592-605. PMID: 24009064
40. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol. 1999; 26:60-70.
41. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002; 20:719-26. PMID: 11821453
42. Tanner M, Kapanen AI, Junttila T, Raheem O, Grenman S, Elo J, et al. Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer. Mol Cancer Ther. 2004; 3:1585-92. PMID: 15634652